Cargando…
Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
INTRODUCTION: Triple-negative breast cancers (TNBCs) are characterised by lack of expression of hormone receptors and epidermal growth factor receptor 2 (HER-2). As they frequently express epidermal growth factor receptors (EGFRs), anti-EGFR therapies are currently assessed for this breast cancer su...
Autores principales: | Jacot, William, Lopez-Crapez, Evelyne, Thezenas, Simon, Senal, Romain, Fina, Frédéric, Bibeau, Frédéric, Romieu, Gilles, Lamy, Pierre-Jean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326575/ https://www.ncbi.nlm.nih.gov/pubmed/22192147 http://dx.doi.org/10.1186/bcr3079 |
Ejemplares similares
-
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer
por: Jacot, William, et al.
Publicado: (2013) -
High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers
por: Jacot, William, et al.
Publicado: (2015) -
Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients
por: Darlix, Amélie, et al.
Publicado: (2016) -
Journey of CAR T-cells: Emphasising the concepts and advancements in breast cancer (Review)
por: Kausar, Mohd Adnan, et al.
Publicado: (2023) -
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers
por: Guiu, Séverine, et al.
Publicado: (2018)